CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress

Access the CEO Connect segment here

HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor CEO Connect Segment.

As part of the segment, Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value. Additionally, Mr. Levin discussed the strategy for pipeline development and securing a new asset, key milestones investors should monitor to evaluate execution of the strategy and the Company's broader growth outlook and investment thesis moving forward.

The Virtual Investor CEO Connect segment is accessible here.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.

For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.

CONTACTS

Investor Relations Contact

JTC Team, LLC Jenene Thomas 908.824.0775 [email protected]

Business Development Contact

CNS Pharmaceuticals, Inc. Dylan Wenke, Chief Business Officer [email protected]

SOURCE: CNS Pharmaceuticals, Inc.

View the original

press release

on ACCESS Newswire